Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $273,980.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ:KNSA opened at $19.74 on Friday. The stock has a market capitalization of $1.43 billion, a P/E ratio of -140.99 and a beta of 0.32. The company has a 50 day moving average price of $19.82 and a 200 day moving average price of $22.89. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Analyst Ratings Changes

Several analysts have recently weighed in on KNSA shares. Evercore ISI increased their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $36.60.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $50,000. CWM LLC lifted its holdings in Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after buying an additional 1,998 shares in the last quarter. nVerses Capital LLC acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $80,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals during the 4th quarter worth approximately $158,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Kiniksa Pharmaceuticals by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock worth $168,000 after buying an additional 4,575 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.